BIOMAT Database Logo BIOMAT Database Logo

Evaluation of a new bronchodilating compound (broxaterol) administered as a pressurized aerosol. 1987

M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco

The bronchodilating activity and the tolerability of a new beta 2-agonist, broxaterol hydrochloride, administered in single doses of 200 and 400 micrograms as pressurized aerosol were studied in 12 adult patients with reversible airway obstruction, taking placebo as a control. A double-blind three-way cross-over design using a series of randomly chosen latin squares was employed. FVC, FEV1, MMEF, heart rate, and blood pressure were measured immediately before and 7.5, 15, 30, 60, 120, 180, and 240 min after each treatment. Our results show that broxaterol is an effective bronchodilating drug with a dose-related activity. The areas under the curves of the changes in FVC, FEV1, and MMEF after the 400 micrograms dose were found to be significantly greater as compared to the 200 micrograms dose. Both broxaterol doses produced significant increases in all the spirometric indices already at the first measurement, i.e., 7.5 min after treatment. Broxaterol 400 micrograms induced significant increases in FVC, FEV1, and MMEF through at least 4 h. The tolerability of the new compound was good.

UI MeSH Term Description Entries
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008450 Maximal Midexpiratory Flow Rate Measurement of rate of airflow over the middle half of a FORCED VITAL CAPACITY determination (from the 25 percent level to the 75 percent level). Common abbreviations are MMFR and FEF 25%-75%. Forced Expiratory Flow 025-075 Percent,FEF 25-75 Percent,Flow Rate, Maximal Midexpiratory,MMFR,25-75 Percent, FEF,25-75 Percents, FEF,FEF 25 75 Percent,FEF 25-75 Percents,Forced Expiratory Flow 025 075 Percent,Percent, FEF 25-75,Percents, FEF 25-75
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010080 Oxazoles Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. Oxazole,1,3-Oxazolium-5-Oxides,Munchnones,1,3 Oxazolium 5 Oxides
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002000 Bronchospirometry Spirometric technique in which the volume of air breathed in the right and left lung is recorded separately. Bronchospirometries
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Evaluation of the bronchodilating activity and the tolerability of broxaterol administered as a solution by inhalation.
May 1993, Arzneimittel-Forschung,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Early bronchodilating effect of a new oral beta-2-receptor agonist (broxaterol) in bronchial asthma.
January 1988, Respiration; international review of thoracic diseases,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Evaluation of a breath actuated pressurized aerosol.
January 1976, Clinical allergy,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Dose-response comparison of broxaterol and salbutamol pressurized aerosols.
January 1990, European journal of clinical pharmacology,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Bronchodilating effect of terbutaline aerosol.
June 1978, Clinical pharmacology and therapeutics,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Evaluation of a Novel Prototype for Pressurized Intraperitoneal Aerosol Chemotherapy.
March 2020, Cancers,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Experimental evaluation of icodextrin delivery as pressurized aerosol (PIPAC): Antiadhesive and cytotoxic effects.
June 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
HEPARIN ADMINISTERED AS AN AEROSOL.
May 1965, Vascular diseases,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Pressurized aerosol bronchodilator instruction.
July 1983, Chest,
M Robuschi, and P Simone, and A Vaghi, and G P Ventresca, and S Bianco
Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler.
May 1993, Chest,
Copied contents to your clipboard!